We are live on ! Find out more
BBIO icon

BridgeBio Pharma
BBIO

75 hedge funds and large institutions have $2.22B invested in BridgeBio Pharma in 2019 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 18

23% more funds holding

Funds holding: 61 → 75 (+14)

20% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 15

1.58% more ownership

Funds ownership: 86.89% → 88.47% (+1.6%)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

18% less capital invested

Capital invested by funds: $2.7B → $2.22B (-$478M)

Holders
75
Holders Change
+14
Holders Change %
+22.95%
% of All Funds
1.64%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.11%
New
33
Increased
18
Reduced
15
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
+$56.3M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$41.7M
3
BlackRock
BlackRock
New York
+$39.3M
4
TCM
TimesSquare Capital Management
New York
+$10.7M
5
State Street
State Street
Massachusetts
+$9.73M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$10.5M
2
Millennium Management
Millennium Management
New York
-$9.48M
3
JP Morgan Chase
JP Morgan Chase
New York
-$9.09M
4
Fidelity International
Fidelity International
Bermuda
-$7.81M
5
SM
SCGE Management
California
-$4.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
Norges Bank
26
Norges Bank
Norway
$3.22M -$4.15M -150,000 -50%
Charles Schwab
27
Charles Schwab
California
$2.71M +$3.49M +126,243 New
FIM
28
Fernwood Investment Management
Massachusetts
$2.04M +$2.63M +95,200 New
N
29
Nuveen
North Carolina
$1.88M +$2.42M +87,372 New
UBS AM
30
UBS AM
Illinois
$1.65M +$54K +1,951 +3%
PAMU
31
Pictet Asset Management (UK)
United Kingdom
$1.32M -$1.07M -38,562 -39%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$1.3M +$1.67M +60,373 New
TAM
33
Tiverton Asset Management
Delaware
$1.1M +$1.34M +48,585 +1,735%
RCM
34
Ratan Capital Management
Florida
$999K -$372K -13,452 -22%
Millennium Management
35
Millennium Management
New York
$802K -$9.48M -342,537 -90%
AC
36
Athanor Capital
New York
$793K +$1.02M +36,948 New
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$756K +$974K +35,207 New
State of Wisconsin Investment Board
38
State of Wisconsin Investment Board
Wisconsin
$736K +$949K +34,300 New
UBS Group
39
UBS Group
Switzerland
$723K +$916K +33,099 +5,517%
Ameriprise
40
Ameriprise
Minnesota
$591K +$67.2K +2,429 +10%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$527K +$679K +24,532 New
GC
42
Grace Capital
Massachusetts
$504K +$650K +23,500 New
EAM
43
Erste Asset Management
Austria
$463K +$636K +23,000 New
PPA
44
Parametric Portfolio Associates
Washington
$385K +$496K +17,929 New
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$380K +$490K +17,700 New
ZP
46
Zimmer Partners
New York
$365K – – –
GHCM
47
Glen Harbor Capital Management
California
$348K +$428K +15,470 +2,068%
MWNA
48
Marshall Wace North America
New York
$337K -$948K -34,272 -69%
MIM
49
MetLife Investment Management
New Jersey
$320K +$413K +14,917 New
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$320K +$440K +15,894 New
1
2
3 4

BBIO Hedge Fund Activity: Q3 2019 in Review

75 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q3 2019, worth a combined $2.22B — down 18% from $2.7B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new BBIO positions and 18 closed out — a net gain of 15 holders — while 18 added to existing stakes and 15 trimmed.

The largest buyer was HHLR Advisors, adding an estimated $56.3M. The largest seller was Fidelity Investments, cutting an estimated $10.5M.

  • 75 institutional investors held BridgeBio Pharma (BBIO) as of Q3 2019, up from 61 in Q2 2019.
  • Funds reported $2.22B of BridgeBio Pharma stock for Q3 2019, down 18% quarter-over-quarter.
  • 33 funds opened new BridgeBio Pharma positions in Q3 2019 and 18 closed out, a net change of +15 holders.
  • The largest BridgeBio Pharma buyer in Q3 2019 was HHLR Advisors, an estimated $56.3M added.
  • The largest BridgeBio Pharma seller in Q3 2019 was Fidelity Investments, an estimated $10.5M sold.

Based on aggregated 13F filings for Q3 2019.